Onconova Therapeutics Inc (ONC)

A long road from bench to market

Onconova Therapeutics was founded in 1992 as an early player in rational drug design—the computational and molecular approach to creating new medicines rather than waiting for serendipitous discovery. For its first two decades, the company operated as a traditional small biotech: investing in research, running laboratory studies, and advancing the most promising compounds into clinical trials. Progress was steady but slow, as is typical in drug development.

The company’s lead program, rigosertib, is a small-molecule drug designed to target a specific cellular pathway that is often defective in cancer cells. The compound showed activity in laboratory and early human studies in myelodysplastic syndromes (MDS), a serious blood cancer, and in other tumor types. However, the drug’s path to approval has been uncertain, with clinical trials producing mixed results. Onconova has pursued partnerships and licensing agreements in an effort to advance rigosertib and to create revenue opportunities, particularly in China and Asian markets where some of the company’s programs have gained regulatory interest.

The structure of a clinical-stage biotech

Unlike a profitable company that generates revenue from products, a clinical-stage biotech like Onconova operates differently. It has a research team, chemists, biologists, and clinicians who design drugs and run experiments. It has no meaningful product revenue. Instead, it burns through cash—funding salaries, lab equipment, clinical trial costs, and regulatory submissions. That burn rate is a critical number: it tells you how long the company can operate before it runs out of money.

Onconova has funded this research through a combination of equity issuance (selling shares to investors), debt, and occasionally licensing agreements or milestone payments from pharmaceutical partners. The company has also pursued government grants and research collaborations that can offset some costs. However, the fundamental model is that the company spends money now on research, hoping that a drug candidate will succeed in clinical trials, gain regulatory approval, and eventually generate large sales that recover the investment.

The clinical-trial gauntlet

Onconova’s rigosertib program has been tested in human patients through multiple clinical trials. Early studies suggested activity—meaning the drug showed some ability to kill or control cancer cells and had acceptable safety. However, rigosertib’s path through larger, more rigorous trials has been slower and less conclusive than hoped. This is typical in oncology: many promising compounds fail or underperform in larger trials.

The company has pursued a strategy of seeking approval in specific patient populations or cancer types where the drug showed the strongest signal. It has also licensed rights to rigosertib and other compounds to partners in specific regions, generating milestone payments and royalties that can offset research costs. For example, partnerships in China have advanced rigosertib in certain blood cancers where there is significant unmet need and potential market opportunity.

Capital structure and survival

A critical fact about Onconova is that it is a pre-revenue company entirely dependent on external capital to survive. It must raise money periodically to fund ongoing research and clinical trials. This can come from equity offerings (diluting existing shareholders), debt, or partnerships that bring in cash. When capital markets are open and investors are enthusiastic about biotech, it is easier for Onconova to raise money. When capital markets are tight or investors are skeptical, it is harder and more expensive.

This makes Onconova inherently higher-risk than an operating company with stable revenue. If the company cannot raise capital when it is needed, it will run out of money and may need to shut down operations, merge with a partner, or drastically reduce scope. On the other hand, if one of its programs succeeds in clinical trials and gains approval, the value could be enormous—a single approved oncology drug can generate billions in sales.

The bet and the uncertainty

Investing in Onconova is a bet on the company’s drug candidates, particularly rigosertib. The basic questions are: Will rigosertib work better than other drugs in its class? Can the company afford to complete necessary clinical trials? Will regulatory agencies approve the drug based on trial data? And if approved, will it be prescribed and generate meaningful revenue?

None of these questions have certain answers. Rigosertib has been in development for many years, and its clinical benefit remains unclear. The company faces competition from other oncology drugs and from larger pharmaceutical companies with more resources. The regulatory and commercial risks are high.

Partnerships and strategic direction

Recent strategic moves have emphasized licensing and partnerships rather than an all-in bet on Onconova’s own pipeline. The company has licensed drugs to partners in specific regions, participated in research collaborations, and pursued milestone opportunities. This approach reduces cash burn by sharing development costs, but it also means that any success is shared with partners—Onconova may not capture the full value of a successful drug.

How to research Onconova

For clinical-stage companies like Onconova, research is specialized. Start with the company’s filings with the SEC (10-K and quarterly 10-Qs at CIK 0001651308), which lay out the status of each drug program, the cash position, and the burn rate. Read the management discussion to understand the company’s capital strategy and partnerships.

Then examine the clinical data on rigosertib and any other programs. ClinicalTrials.gov is a public database where you can look up the company’s trials, find out what they tested and what the results were. Scientific publications in peer-reviewed journals can provide detail on efficacy and safety.

Finally, understand the capital position: How much cash does the company have? What is the quarterly burn rate? When will it likely need to raise capital again? These questions determine the near-term survival and dilution risk for shareholders.

Investing in a pre-clinical stage biotech like Onconova is not a passive holding—it requires understanding of both the drug development process and the company’s specific pipeline and financial position.